Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,010 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Event Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

NCT06789601
View directory record Official record
Conditions
Malignancy, Immune Related Adverse Events
Interventions
Informatics system for eligibility monitoring, Standard eligibility monitoring
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

NCT00006105
View directory record Official record
Conditions
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 4:36 PM EDT
Terminated Phase 4 Interventional Results available

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494
View directory record Official record
Conditions
Unresectable Stage III NSCLC
Interventions
Multiparametric Mobile Technology
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Terminated Not applicable Interventional Results available

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV, Drug-Induced Liver Injury
Interventions
Shear Wave sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 22, 2026, 4:36 PM EDT
Completed No phase listed Observational Results available

Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

NCT03468309
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Genecept Assay and G-DIG decision tool
Genetic
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
331,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003144
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

NCT03518034
View directory record Official record
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
5,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
379
States / cities
Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 22, 2026, 4:36 PM EDT
Not listed Phase 4 Interventional

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

NCT00751153
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Atazanavir
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2008 · Synced Oct 22, 2026, 4:36 PM EDT
Completed No phase listed Observational Results available

Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty

NCT04821245
View directory record Official record
Conditions
Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction
Interventions
Not listed
Lead sponsor
Benaroya Research Institute
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 22, 2026, 4:36 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

COVID-19 Reactogenicity

NCT07051031
View directory record Official record
Conditions
COVID-19
Interventions
Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
Drug
Lead sponsor
Marcel Curlin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 2 Interventional

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

NCT07226791
View directory record Official record
Conditions
Ventral Hernia
Interventions
AGN-151607-DP, Placebo for AGN-151607-DP
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Riverside, California • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of a Novel Coaching Program on Medical Errors and Well-Being of Physicians

NCT05557981
View directory record Official record
Conditions
Burnout, Adverse Event, Medical Education
Interventions
Coaching
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

NCT04912063
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Lemzoparlimab, Azacitidine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional Results available

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

NCT05446129
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ezabenlimab, BI 765063, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting No phase listed Observational

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

NCT01258231
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery, Genetic Predisposition to Disease, Atrial Fibrillation, Myocardial Infarction, Heart Failure
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 22, 2026, 4:36 PM EDT